The growth potential of Voyager Therapeutics is intrinsically tied to the clinical success of its proprietary TRACER capsid discovery platform and its expanding pipeline of neurogenetic medicines targeting complex conditions like Alzheimer's and Parkinson's disease. Successful clinical trials, regulatory approvals, and expansion of lucrative licensing partnerships with global pharmaceutical giants could unlock substantial value. However, because it operates as a pre-resource development firm, its growth trajectory remains highly speculative and sensitive to clinical outcomes.